Loading
The PBD dimer SG3199 crosslinks DNA in the minor groove without distorting it, so cells fail to detect the damage; it kills at picomolar concentrations, so ADCs need only a low drug-to-antibody ratio. Fluid retention, skin reactions and light sensitivity stopped several programmes; loncastuximab tesirine in large B-cell lymphoma is the approved example.
Pyrrolobenzodiazepine dimers bind in the minor groove and crosslink DNA without distorting it, so cells struggle to detect and repair the damage. Potency is picomolar, allowing low drug-to-antibody ratios. Fluid retention, skin reactions and light sensitivity are characteristic, and several PBD programmes were stopped for toxicity (for example vadastuximab talirine). Loncastuximab tesirine in large B-cell lymphoma is the successful case.
Showing the molecule this term concerns: Loncastuximab tesirine.
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC).
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC).
Shares Loncastuximab tesirine, Antibody-drug conjugate (ADC).